MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Aileron Therapeutics Market Cap 2011-2026 | ALRN
As of March 25, 2026 Aileron Therapeutics has a market cap of $ 9.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aileron Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.2 M | 27.3 M | 6.67 M | 1.9 M | 59.8 M | 17.5 M | 15.9 M | 68.8 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.8 M | 1.9 M | 29.5 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 215.54 | -1.16 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 3.88 | -1.27 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 19.23 | - | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 8.18 | -2.97 % | $ 109 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
28.2 M | $ 0.71 | 17.15 % | $ 8.13 M | Israel |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.32 | -5.71 % | $ 337 M | Britain |
 |
CytomX Therapeutics
CTMX
|
931 M | $ 4.24 | -4.83 % | $ 585 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
5.58 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | USA |
 |
Genmab A/S
GMAB
|
25 B | $ 25.81 | 0.51 % | $ 16.6 B | Danmark |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.65 | 0.76 % | $ 16.6 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
116 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 22.97 | -3.53 % | $ 618 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 41.57 | 0.39 % | $ 11.3 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Fortress Biotech
FBIO
|
32.4 M | $ 2.92 | -2.01 % | $ 60.7 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.31 | -2.49 % | $ 826 M | Canada |
 |
Homology Medicines
FIXX
|
76.3 M | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |